Center-Authored Papers

Filters: Author is Friedberg, Jonathan W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
U
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES et al..  2016.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(17):2020-+. Abstract
R
Press OW, Friedberg JW.  2017.  Reply to H.J.A. Adams et al and E.A. Hawkes et al.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(3):373.
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L et al..  2017.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.. Journal of the National Cancer Institute. 109(1) Abstract
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA et al..  2016.  RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.. British journal of haematology. Abstract
Sehn LH, Goy A, Offner FC, Martinelli G, Caballero DM, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE et al..  2015.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(30):3467-3474. Abstract
Friedberg JW, Unger JM, Burack RW, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP et al..  2014.  R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.. British journal of haematology. Abstract
P
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20. Abstract
Till BG, Li H, Bernstein SH, Fisher RI, Burack RW, Rimsza LM, Floyd JD, Dasilva MA, Moore DF, Pozdnyakova O et al..  2016.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.. British journal of haematology. 172(2):208-218. Abstract
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox A-M et al..  2016.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.. Leukemia & lymphoma. 57(10):2359-2369. Abstract
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM et al..  2015.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC et al..  2015.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.. Blood. 126(26):2798-2804. Abstract
O
Puvvada SD, Stiff PJ, LeBlanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN et al..  2016.  Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.. British journal of haematology. 174(5):686-691. Abstract
L
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L et al..  2015.  Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13):1482-90. Abstract
I
Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA et al..  2017.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.. Blood.
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract
G
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ et al..  2015.  Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.. American journal of hematology. Abstract
F
Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM, Friedberg JW.  2016.  Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.. Leukemia & lymphoma. :1-5.
E
Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW et al..  2015.  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.. Blood. 125(6):992-8. Abstract
C
Stephens DM, Li H, Leblanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM.  2016.  Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(25):2997-3004. Abstract
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32. Abstract
B
Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J et al..  2013.  Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Lymphomas: A Retrospective Evaluation of Safety and Efficacy.. Leukemia & lymphoma. Abstract
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH et al..  2016.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.. Journal of the National Cancer Institute. 108(12) Abstract
A
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract